12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tradjenta: Interim Phase III data

Interim data from a double-blind Phase III trial in 1,261 Type II diabetics inadequately controlled on basal insulin therapy with or without metformin and/or Actos pioglitazone showed that once-daily 5 mg Tradjenta as an add-on therapy met the primary endpoint of reducing HbA1c from baseline to...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >